SWX:NWRNPharmaceuticals
Newron Pharmaceuticals (SWX:NWRN) Near Breakeven EPS Rekindles Debate On Rich P/S Multiple
Newron Pharmaceuticals (SWX:NWRN) has opened FY 2025 with first half revenue of €11.9 million and a basic EPS loss of €0.00, setting a cautious tone against a share price of CHF 14.64. Over recent periods, the company has seen revenue move from €3.4 million in H1 2024 to €48.0 million in H2 2024 and then to €11.9 million in H1 2025. Basic EPS has shifted from a loss of €0.51 in H1 2024 to a profit of €1.37 in H2 2024 and back to a marginal loss in the latest half, leaving investors focused on...